June 2019 Volume 15, Issue 6

Volume 15, Issue 6 | June 2019

June 2019

In this Issue

Discovery

Drug Discovery News Placeholder Image

Alnylam and Regeneron join on RNAi therapeutics

Companies focus on ocular and CNS, and advance select programs with targets expressed in the liver
Drug Discovery News Placeholder Image

Duo ‘AIMS’ at AI-powered discovery efforts

Atomwise AI platform narrows the field in drug discovery
Drug Discovery News Placeholder Image

AI gains traction

Three companies kick off the second quarter with AI-based announcements
Drug Discovery News Placeholder Image

A new roadmap

Scripps publishes new study on neurons and neural conditioning
Drug Discovery News Placeholder Image

A model for heart valve disease drug discovery

New physiological tool featured in published paper in Experimental Biology and Medicine

Research & Development

Drug Discovery News Placeholder Image

Accelerating AI adoption

Group tries to reduce obstacles to AI use in life sciences
Drug Discovery News Placeholder Image

A gene association

Mount Sinai researchers identify twenty novel gene associations with bipolar disorder
Drug Discovery News Placeholder Image

Setting the clocks ahead for cardiac cells

Researchers determine a method for accelerating the maturation of iPSCs into cardiomyocytes
Drug Discovery News Placeholder Image

Q BioMed speaks up for autism

Research shows major breakthrough with first biomarkers for pediatric nonverbal autism subgroup

Business & Government Policy

Drug Discovery News Placeholder Image

Clarifying the finish line

FDA releases final guidance on how interchangeability will be determined for biosimilars
Drug Discovery News Placeholder Image

ProBioGen and Vaccitech sign license deal for tech platform

AGE1.CR allows large-scale manufacturing with higher production yields
Drug Discovery News Placeholder Image

On the cutting edge

A roundup of instrumentation, software and other tools and technology news
Drug Discovery News Placeholder Image

Targets acquired

A look at a few recent M&A deals in the pharma world

Special Reports

Drug Discovery News Placeholder Image

Special Report on Cancer: Metabolic renaissance?

Drilling to the core of life itself: Researchers go deep into the world of metabolomics to find new therapeutic possibilities with metabo-oncology

Feature

Drug Discovery News Placeholder Image

IO Summit Show Preview: Boston-bound for immuno-oncology

Come to Boston again, or for the first time, to get the insight on immuno-oncology

Editor's Focus

Drug Discovery News Placeholder Image

Editor’s focus: The gene genie is out of the bottle

Our progress in terms of genetics and genomics research has been quick since the Human Genome Project wrapped up, and that's good, but let's also take note of some of the warning flags that might be cropping up now

Q&A

Drug Discovery News Placeholder Image

Q&A: Current affairs for CAR T

Celyad details current obstacles faced by CAR T approaches, and its own efforts to address them

Commentary

Drug Discovery News Placeholder Image

Two R&D cultures: Creativity and consistency

There is a balance that is necessary in research and development, so let's not lose sight of keeping it overall, even if many individual people (and companies and institutions) often trend more one direction or the other
Drug Discovery News Placeholder Image

Guest Commentary: The growing potential of CAR T-cell therapy

Andrea Toell of Lonza shares how CAR T cells are transforming immuno-oncology

Clinical Trials

Drug Discovery News Placeholder Image

New Spinraza data

Biogen presents data affirming longer-term safety and durability of Spinraza (nusinersen) treatment
Drug Discovery News Placeholder Image

Attacking Alzheimer's disease via amyloids

Consortium studies Eisai drug candidates BAN2401 and elenbecestat
Drug Discovery News Placeholder Image

Pneumococcal vaccine seems on track for Phase 3

Merck shares data about increased immune response from V114 in Phase 2 trials
Drug Discovery News Placeholder Image

A sight for sore eyes

GenSight reports marked visual improvement in Phase 3 study of rare eye disease

Contract Services

Drug Discovery News Placeholder Image

Charles River invests in Resero Analytics

Access to TurboToxicology expected to provide faster delivery of high-quality toxicology reports
Drug Discovery News Placeholder Image

Shooting for the stars

Syneos Health takes top honor at inaugural ACRP All-Stars Challenge
Drug Discovery News Placeholder Image

Forward with vaccines

WuXi Biologics signs on for long-term vaccine manufacturing contract

Diagnostics

Drug Discovery News Placeholder Image

ArcherDX attracts money and talent

Company looks to advance its Reveal ctDNA 20 kits and AMP-based target enrichment system
Drug Discovery News Placeholder Image

An anti-PD-1 antibody collaboration

Arcus and Strata announce clinical development collaboration for AB122 and predictive biomarkers
Drug Discovery News Placeholder Image

A clearer risk assessment

Exagen’s PC4d biomarker shows promise in determining lupus patients at risk of thrombosis
Drug Discovery News Placeholder Image

A ‘breakthrough’ for Caris

MI Transcriptome companion diagnostic test receives FDA Breakthrough Device Designation

Preclinical

Drug Discovery News Placeholder Image

Epilepsy faces new foe in miRNAs

InteRNA and UMC Utrecht publish preclinical evidence for potential of therapeutic aimed at miR-135a
Drug Discovery News Placeholder Image

Bridging the SynGAP in autism

A new study finds gene repair improves memory and seizures in adult autism model
Drug Discovery News Placeholder Image

Taking it straight to the eye

Vector platform delivers gene therapy to the retina
Drug Discovery News Placeholder Image

Two For One

CytoDyn seeks to evaluate PRO 140 in breast cancer and NASH
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Gold circles with attached purple corkscrew shapes represent gold nanoparticles against a black background.

Driving gene therapy with nonviral vectors 

Learn why nonviral vectors are on the rise in gene therapy development.
A 3D digital illustration of a viral spike protein on a cell surface, surrounded by colorful, floating antibodies in the background

Milestone: Leapfrogging to quantitative, high throughput protein detection and analysis

Researchers continuously push the boundaries of what’s possible with protein analysis tools.
Blue cancer cells attached to a cellular surface against a bright blue background in a 3D rendering of a cancer infection.

Advancing immuno-oncology research with cellular assays

Explore critical insights into immunogenicity and immunotoxicity assays for cancer therapies.
Drug Discovery News November 2024 Issue
Latest IssueVolume 20 • Issue 6 • November 2024

November 2024

November 2024 Issue

Explore this issue